Diligent pharma solutions for a changing global market

Portfolio evaluation and business development for formulations and APIs, across regulated and emerging markets. We enable you to make informed decisions with confidence.

Send an enquiry View licensing opportunities

30+ years of pharma experience. 1000+ products evaluated. Multiple licensing collaborations facilitated.

Trusted for Evaluation
Defined by Expertise
Driven by Excellence

EuropeUnited KingdomLatin AmericaUnited StatesCanadaEuropeUnited KingdomLatin AmericaUnited StatesCanada

Our Core Services

From portfolio evaluation and market intelligence to business development and licensing, we provide focused expertise to support informed decisions and strategic partnerships.

Pavani JSL, Founder

With over 30 years of pharmaceutical expertise, Pavani JSL is a visionary strategist enabling companies toward sustainable global growth.

Pavani leads Pavani Consultancy Services, working directly with C-suite executives to optimise pharmaceutical portfolios, identify market opportunities and facilitate strategic partnerships across the US, EU and emerging markets. Her extensive product and portfolio experience, combined with a strong global industry network, enables structured strategies grounded in commercial insight and practical execution.

Career with Glaxo, Dr. Reddy’s, Aurobindo, Mylan and Hetero

Read her profile

Why partner with us

Experience, expertise and excellence

Deep industry experience: 30+ years in portfolio and BD facilitation.
Proven track record: 1000+ evaluations, multiple deals.
Functional expertise: One-stop expertise across Formulations and APIs.
Strong global network: EU-GMP and USFDA CDMOs, CMOs and CROs.
Confidential and agile: Fast response, proactive follow-up.

Est. 2019

Seven years of diligent pharma solutions

Thank you to our partners and clients for seven years of trust.

Built on trusted experiences

Designations are as at the time each testimonial was given.

A place for diligent pharma solutions

Pavani Consultancy Services, established in Hyderabad in 2019, is a pharmaceutical portfolio and business development consultancy. We evaluate products across the US, EU and emerging markets. We facilitate licensing and strategic partnerships between pharmaceutical companies, CDMOs, CMOs and CROs. PCS also publishes PULSE, a monthly report tracking US FDA approvals.

Trusted for Evaluation
Defined by Expertise
Driven by Excellence

Meet our founder

Pavani JSL is an accomplished pharmaceutical industry expert and consultant with over three decades of experience in strategic leadership and global business development.

Founder and Principal Consultant: Leads Pavani Consultancy Services, delivering strategic advisory in pharmaceutical portfolio management, market intelligence and business development to support informed decision-making and sustainable growth.
Core competencies: Portfolio strategy, Global in-licensing and out-licensing, market intelligence, strategic business development, and long-term growth execution.
Impact: Enabling pharmaceutical manufacturers and life sciences companies to optimise product portfolios, identify global market opportunities, prioritise investments and establish strategic partnerships.

When you partner with Pavani Consultancy Services, you gain direct access to an experienced pharmaceutical consultant with a Master’s in Business Administration and an International Business programme from IIM Calcutta, backed by extensive experience evaluating hundreds of products across the US, EU and ROW markets.

Our experience, structured approach and global perspective combine rigorous evaluation methodologies, strategic portfolio insights, KOL-driven marketing strategies and a strong network of global industry connections to support informed leadership decisions and sustainable business growth.

ExperienceApproachGlobal Perspective

Milestone achievements

1000+

Products evaluated

For active development across the US, EU and ROW markets.

5year

Strategic portfolio roadmaps

Designed for global portfolios.

Multiple

Companies, business development

Collaborations facilitated and major licensing deals closed in respiratory, aesthetic and gynaecological therapies.

Where it all comes together

A career spanning five companies, bringing together expertise in pharmaceutical portfolio management and business development at Pavani Consultancy Services.
Select a company to explore her role and experience.

ServicesPortfolio Evaluation and Management

Know which products deserve your investment before you commit to them

Request a demo

1000+ products evaluated across varied dosage forms and therapeutic areas, guiding launches in the US, EU, SE Asia and LATAM markets.

What We Do

We enable pharmaceutical companies to build commercially viable product portfolios across the US, EU and emerging markets.

Working directly with C-suite leaders, we evaluate opportunities at the product, market, dosage form and therapy levels. Our recommendations are supported by market intelligence, commercial forecasting and robust business cases to enable informed investment decisions.

How an Assessment Helps You

Make Go / No-Go Decisions Before Investing: Evaluate each product's commercial potential before committing development budgets.
Allocate Budgets to the Right Products: Prioritise opportunities based on commercial attractiveness, directing limited R&D resources towards products with stronger return potential.
Plan Around Market Entry Windows: Map patent and exclusivity timelines, earliest filing opportunities and projected launch dates to identify viable entry windows.
Understand the Competitive Landscape Early: Assess existing DMFs, CEPs, ANDAs and Marketing Authorisations to understand competition and anticipate market crowding at the time of entry.
Evaluate API and Formulation Opportunities Separately: Assess each opportunity independently, recognising that API and formulation opportunities may have different commercial potential and investment priorities.
Forecast Future Market Potential: Project market volumes and values, incorporating generic entry timelines and anticipated price erosion to estimate market conditions at launch.
Build Business Cases for Investment Decisions: Develop three-scenario revenue and margin projections to support internal investment approvals and partner discussions.

Three Services, Curated to Your Needs.

Engage any service independently or combine them to suit your objectives. Each engagement is tailored to your product portfolio, target markets and business priorities.

Detailed Portfolio Evaluation

Carried out at product, market, dosage form or therapy level.

Product synopsis
Preliminary IP assessment
Mechanism of action
Comparative molecule assessment with clinical trials
Bio guidance for the US and EU
Competitive scenario: API (DMFs, CEPs) and formulation approvals (ANDAs, MAs)
Market assessment in volumes and values

How an evaluation flows

From executive summary to strategic recommendation, explore the key sections of a typical evaluation. Click any section to see how the analysis is presented. Examples are illustrative only and contain no actual figures.

Illustrative example

Forecasting for Regulated Markets

Forward view of the market you would be entering.

Volume and value forecasts by country
Generic entry timing and price erosion built in
API consumption derived from formulation volumes
Assumptions stated so they can be challenged and updated

Market forecast with generic entryIllustrative. Shape of a typical forecast: volume grows while value falls once generics enter.

Business Case for Regulated Markets

Your own revenue and margin picture, under three scenarios.

PessimisticRealisticOptimistic

Market share, volume, revenue and gross margin per scenario
Separate cases for formulations and API
Country-by-country view and launch sequence
A clear recommendation: proceed, proceed with caution, or drop

Recent Portfolio Evaluations

Technologies

Proprietary technology fitment
Nanoparticles
Extrusion
Spheronization
Transdermal patches

Product types

ODTs
ODFs
Oral solid dosages
Suppositories
Liquids
Injections
505(b)(2) opportunities

Therapy areas

Oncology (unexpired patents)
ADHD
Ophthalmics
Topicals
Hemostatic agents
Wound management

Evaluated across the US, EU, SE Asia and LATAM markets, along with numerous individual product-level evaluations.

Walk through a sample evaluation

We would be happy to walk you through a sample evaluation, forecast and business case.

Request a demo

PULSE – Product approvals Updates & Landscape Summary Enabler

ServicesPULSE

US FDA approvals, enabling decision making

PULSE is a decision enabler. Every month it turns US FDA approvals into a landscape report that tells you where competition is thin, where API supply is tight and what is about to launch, so your product choices rest on current evidence.

PULSE is a subscription report. It is more than an Excel file: subscribers get interactive data views alongside the workbook.

Request a demo

Interactive data views, tailored to your specific requirements

What you want.
Way you want.
When you want.

Which product received approval
Who received approval
How many players received approval so far
How many DMF holders are active

Who PULSE is for

Portfolio managers, BD and in-licensing teams, API sourcing teams, regulatory and ANDA strategy, and CDMOs planning capacity.

Inside The Report

A glimpse into the visual intelligence behind our reports. Explore selected dashboard layouts, with the full report offering an extensive range of dashboards, graphical analyses and interactive features. All examples are illustrative.

Sample layout

What you receive, and the decisions it enables

Each dashboard answers a question your portfolio and BD teams have to decide on.

Every subscriber receives

A monthly report. The full PULSE workbook every month, turning US FDA approvals into a landscape you can act on.

You receive
Competition and API supply watch
Molecules with few active generics or few DMF holders, so you can see where competition is thin and API supply is tight.
So you can decide
Which molecules to add to the pipeline
PULSE shows approvals with five or fewer active generics, and first and sole generics.
You receive
Launch watch
Tentative approvals tracked by molecule, so you know which generics are about to reach the market.
So you can decide
Whether to continue or drop a product in development
PULSE shows how many competitors are already approved and how fast the field is filling.
You receive
Interactive data views
Filter by month, company, dosage form, route and pathway to build the view you need.
So you can decide
Which dosage forms and capabilities to invest in
PULSE shows the trend by dosage form, route and injectables.
You receive
Insights and strategic implications
A summary of what changed and what it means for your portfolio and partnering choices.
So you can decide
Which companies to benchmark and what you are up against
PULSE presents US FDA approvals company-wise, consolidating related groups to help you benchmark peers, track their approval activity and understand the competitive landscape.

See PULSE for yourself

Request a demo

Select the areas you wish to discuss

Select the services you would like to discuss. Adding a message is optional.

Portfolio Evaluation and ManagementEvaluation, forecasting and three-scenario business cases

Business Development FacilitationLicensing opportunities and partnerships, from partner scouting to alliance management

PULSE subscriptionA monthly report on US FDA approvals

Something elsePlease describe your requirement

Privacy & Cookies

Last updated: October 2026

Who we are

This website is operated by Pavani Consultancy Services, Hyderabad, Telangana, India. For any privacy question, write to pavanijsl@pavanics.com.

What we collect

Only what you type into our enquiry, demo and licensing forms: name, company, email, phone (optional) and message. The details are emailed to our team and used to reply to you and to keep a business record of the enquiry.

Spam protection

Our forms use Cloudflare Turnstile to confirm that a real person is sending the enquiry. Turnstile receives technical information from your browser for this purpose only.

Your rights

You may ask us to access, correct or delete the personal data we hold about you, or to stop contacting you, by emailing us. We handle requests under applicable data protection law, including India’s Digital Personal Data Protection Act, 2023 and, for visitors in the EU or UK, the GDPR.

Cookies and similar storage

Name or provider	Purpose	Type	Duration
pcs_consent (this site)	Remembers your cookie choice	Essential	Until you clear your browser data or change your choice
Cloudflare Turnstile	Spam protection on forms	Essential (security)	Session
Elfsight	Shows our LinkedIn posts on the Company Updates page. May set its own cookies	Third-party content, only with your permission	Set by Elfsight

We do not use advertising or analytics cookies. You can change your choice at any time using Cookie settings in the footer. Our fonts are served from this website, so no font requests are made to third parties.

Links to LinkedIn and other sites are governed by their own policies.

Diligent pharma solutions for a changing global market

Our Core Services

Pavani JSL, Founder

Why partner with us

Seven years of diligent pharma solutions

Built on trusted experiences

A place for diligent pharma solutions

Meet our founder

Milestone achievements

Products evaluated

Strategic portfolio roadmaps

Companies, business development

Where it all comes together

Know which products deserve your investment before you commit to them

What We Do

How an Assessment Helps You

Three Services, Curated to Your Needs.

Detailed Portfolio Evaluation

How an evaluation flows

Forecasting for Regulated Markets

Business Case for Regulated Markets

Recent Portfolio Evaluations

Technologies

Product types

Therapy areas

Walk through a sample evaluation

From scouting to alliance management

From lead to deal, and beyond

Business models we facilitate

Where we have worked

Collaborations facilitated

Let’s structure your next deal

US FDA approvals, enabling decision making

Who PULSE is for

Inside The Report

What you receive, and the decisions it enables

Competition and API supply watch

Which molecules to add to the pipeline

Launch watch

Whether to continue or drop a product in development

Interactive data views

Which dosage forms and capabilities to invest in

Insights and strategic implications

Which companies to benchmark and what you are up against

See PULSE for yourself

Company Updates

Products available for licensing

Thank you

Privacy & Cookies

Who we are

What we collect

Spam protection

Your rights

Cookies and similar storage